ShangPharma opens pilot plant in Shanghai
For pharma development and cGMP manufacturing
The new multi-purpose pharmaceutical development and cGMP manufacturing facility will allow ShangPharma to support its clients Phase II and Phase III trials, expanding its service offering to include process and formulation r&d, analytical method development and validation, and cGMP manufacturing of intermediates and APIs.
Previously the CRO/CMO provided clients with materials for early discovery and GLP toxicology testing and Phase I clinical trials.
ShangPharma said it might further expand its manufacturing facilities if there is demand for commercial manufacturing of FDA- or EMEA-approved drugs.
The Fengxian facility will operate as a wholly owned subsidiary of the company under the name China Gateway Pharmaceutical Development Co. It includes a pilot plant that supports six separate bays with reactor capacities ranging from 200 to 3,000 litres and other speciality bays with reactor capacities ranging from 50 to 2000 litres for high temperature, cryogenics, highly toxic and pressurised reactions, including hydrogenation.
The company said there are also two cleanroom suites rated at Class 100,000 for isolation, 10 kilo-lab suites for bothnon-cGMP and cGMP manufacturing, as well as a large r&d laboratory for analytical, formulation and process development activities.
In addition, there are separate buildings for utilities, materials management, warehouse storage and waste water treatment with room for further expansion to support commercial manufacturing activities.
Testing of raw materials, intermediates and final products will be carried out at the site. An independent quality assurance department will ensure that materials are manufactured in accordance with cGMP requirements and that established standard operating procedures are followed, the firm said.
You may also like
Trending Articles
You may also like
Pharmaceutical
Optimising process steps and performance with agitated Nutsche filter-dryers
Agitated Nutsche filter dryers (ANFD) streamline solid-liquid separation by performing filtration, dewatering, and drying in a single sealed vessel; an enormous boon in fine chemicals and pharmaceutical production
Pharmaceutical
Automating processes for effective scale-up with the GFD Lab PLUS Filter Dryer
Scale-up is a persistent challenge in fine chemical and pharmaceutical manufacturing. Countless challenges arise when translating workflows from the lab, or pilot-scale, to commercial production. But issues can occur even earlier. Inconsistencies during early development can lead directly to scale-up failures
Design & Build
Deadline is approaching to submit applications for FDA’s PreCheck Pilot Program for pharma industries
The US Food and Drug Administration has opened applications for a scheme to give pharmaceutical manufacturers early guidance for developing new facilities, which will close on March 1